Over 80% cancer antigens are intracellular and cannot be reached by conventional antibodies. Those intracellular antigens are presented in MHC antigen complexes - potential targets for T Cell Receptors (TCR).
MAR (MHC Antigen Receptor) is a class of fully human single domain antibodies that bind to MHC antigen complex, same binding mechanism as TCR. MAR is also called "TCR-like antibody". By binding to MHC antigen complexes, MAR can be used to target at intra-cellular targets, having great potential for cancer immunotherapies.
MAR's advantage over conventional antibodies
More targets: MAR binds to intracellular antigens as presented in the MHC antigen complexes, while conventional antibodies only bind to cell surface antigens. More than 80% cancer antigens are intracellular.
MAR's advantage over TCR
Better native binding specificity and affinity;
Easier to generate and produce.